NewsMV
(Nasdaq: ACAD) released Phase 3 enabling topline results from the Phase 2 portion of the RADIANT clinical trial program.
The data for remlifanserin in Alzheimer's disease psychosis (ADP) show efficacy trends that support continuing Phase 3 development of the 60 mg once-daily dose, while the 30 mg dose showed minimal improvement compared to placebo.
For the primary endpoint, measured as the change in hallucinations and delusions symptoms at week 6, the 60 mg dose demonstrated a change of -12.6 versus -10.4 for placebo.
This result yielded a standardized effect size of 0.26 with a p-value of 0.0603, narrowly missing statistical significance.
Keep reading